TRiCares GmbH and SAS
France, FR · Founded 2018 · 67 employees on LinkedIn · 6 known investors
TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation. The company runs clinical studies across Europe and the US targeting structural heart institutions and cardiac patients.
Founders & leadership
AE
Ahmed ElmouelhiPresident & CEO
EG
Esther GerteisSenior VP Medical & Regulatory Affairs
ML
Michael LitzenburgerVP R&D
Investors · 6
Competitors · 2
by search overlap
Edwards Lifesciences9 shared keywords
Cardiovalve7 shared keywordsCardiovalve develops a transcatheter valve replacement system designed to fit both mitral and tricuspid anatomies via transfemoral delivery, avoiding open heart surgery. The device targets structural heart disease and is currently restricted to research use.
Companies competing with TRiCares GmbH and SAS for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does TRiCares GmbH and SAS do?
- TRiCares develops the Topaz Transfemoral Tricuspid Heart Valve Replacement (TTVR) System, a minimally invasive device for treating tricuspid regurgitation. The company runs clinical studies across Europe and the US targeting structural heart institutions and cardiac patients.
- Who are TRiCares GmbH and SAS's investors?
- TRiCares GmbH and SAS's investors include European Investment Bank, 415 Capital, Andera Partners, Bayern Kapital, BioMedPartners, Karista.
- Where is TRiCares GmbH and SAS headquartered?
- TRiCares GmbH and SAS is headquartered in France, FR.